A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability progression.

Detailed price information for Theravance Bio Ord (TBPH-Q) from The Globe and Mail including charting and trades.

Abstract: As a promising technology in the B5G and 6 G era, integrated sensing and communication (ISAC) can simultaneously support high-quality sensing and communication, and there is a growing ...

Lundbeck announces last patient randomized ahead-of-schedule in phase 3 MASCOT clinical trial: Valby, Denmark Wednesday, March 11, 2026, 13:00 Hrs [IST] H. Lundbeck A/S (Lundbeck) ...

The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

Clinical-stage biotech Alterity Therapeutics has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as it advances its lead drug candidate ATH434 toward a ...

MASCOT is a first-of-its-kind, Phase 3 trial supporting the development of amlenetug, an investigational therapy for people living with multiple system atrophy (MSA), a rare and fatal neurodegenerativ ...

Professor Günter Höglinger, Lead Investigator of the Mascot trial, said: “Completing randomization of a global Phase 3 trial in MSA is a significant achievement for the field.” He added: “Advancing ...

Abstract: This study constructs an innovative event-triggered (ET) fuzzy consensus framework for nonlinear delayed parabolic PDE-based multi-agent systems (MASs) to resist multiple attacks. Firstly, a ...